Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.

Front Immunol · 2021 · PMC8595937 · PMID 34803999

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Although spebrutinib did not demonstrate efficacy in RA, it displayed a strong trend towards improvement in RA clinical efficacy measures as well as a reduction in circulating bone resorption biomarkers, near complete BTK coverage, and a significant reduction in circulating transitional B cells and an increase in naive cells.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.